AG
CLDX icon

Algert Global’s Celldex Therapeutics CLDX Stock Holding History

Algert Global’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.1M Buy
647,836
+432,677
+201% +$14M 0.29% 55
2026
Q1 		$6.82M Buy
215,159
+116,312
+118% +$3.17M 0.1% 343
2025
Q4 		$2.68M Sell
98,847
-4,900
-5% -$129K 0.04% 625
2025
Q3 		$2.68M Sell
103,747
-77,218
-43% -$1.79M 0.04% 597
2025
Q2 		$3.68M Buy
180,965
+47,368
+35% +$922K 0.08% 432
2025
Q1 		$2.42M Buy
133,597
+29,260
+28% +$654K 0.06% 541
2024
Q4 		$2.64M Buy
104,337
+49,354
+90% +$1.34M 0.06% 513
2024
Q3 		$1.87M Sell
54,983
-20,631
-27% -$786K 0.05% 569
2024
Q2 		$2.8M Buy
75,614
+32,564
+76% +$1.23M 0.09% 356
2024
Q1 		$1.81M Buy
43,050
+33,140
+334% +$1.36M 0.07% 442
2023
Q4 		$393K Sell
9,910
-18,920
-66% -$556K 0.02% 883
2023
Q3 		$793K Sell
28,830
-10,650
-27% -$334K 0.04% 616
2023
Q2 		$1.34M Buy
39,480
+15,844
+67% +$534K 0.06% 551
2023
Q1 		$850K Buy
23,636
+15,343
+185% +$662K 0.04% 694
2022
Q4 		$370K Sell
8,293
-14,740
-64% -$526K 0.02% 888
2022
Q3 		$647K Buy
23,033
+4,188
+22% +$128K 0.04% 722
2022
Q2 		$508K Buy
18,845
+4,860
+35% +$141K 0.04% 754
2022
Q1 		$476K Buy
13,985
+6,800
+95% +$217K 0.03% 830
2021
Q4 		$278K Sell
7,185
-970
-12% -$42.3K 0.03% 761
2021
Q3 		$440K Buy
+8,155
New +$383K 0.06% 588
2021
Q1 		– Sell
-10,980
Closed -$192K – 453
2020
Q4 		$192K Sell
10,980
-34,090
-76% -$614K 0.05% 348
2020
Q3 		$668K Buy
+45,070
New +$528K 0.21% 159

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Algert Global's CLDX Position: Q2 2026 in Review

Algert Global increased its Celldex Therapeutics (CLDX) stake by 201% in Q2 2026, buying an estimated $14M and bringing the position to 647,836 shares worth $24.1M. The position accounts for 0.29% of the portfolio, ranked #55.

Algert Global first reported a position in CLDX in Q3 2020 and has held it in 22 quarters since. 254 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Algert Global held 647,836 shares of Celldex Therapeutics worth $24.1M as of Q2 2026.
  • Algert Global bought 432,677 Celldex Therapeutics shares in Q2 2026, an estimated $14M.
  • Celldex Therapeutics made up 0.29% of Algert Global's portfolio in Q2 2026, its #55 holding.
  • Algert Global first reported a position in Celldex Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • 254 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.